drugset
drugset / Trial / NCT04748536

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

NCT04748536 ↗

Phase 1 Completed 18 enrolled Revolo Biotherapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.

Timeline

Start
2021-01-29
Primary completion
2021-04-05
Completion
2021-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject IRL201104 Protein / enzyme biologic — Intravenous

Indications

No indication recorded.